{"disease":{"id":"icu","name":"icu"},"drugs":{"marketed":[{"drug_id":"lenalidomide","indication_name":"Follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revlimid","generic_name":"lenalidomide","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cereblon (component of cullin ring E3 ubiquitin ligase enzyme complex)","drug_class":"Thalidomide analogue","quality_score":10,"revenue":"5809","mechanism":"Lenalidomide targets cereblon to degrade substrate proteins, inducing cytotoxicity and immunomodulation."},{"drug_id":"upadacitinib","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"rituxan","indication_name":"Follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituxan","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody","quality_score":45,"revenue":"3800","mechanism":""},{"drug_id":"desonide","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Verdeso","generic_name":"DESONIDE","company_name":"Padagis Us","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":"2800","mechanism":""},{"drug_id":"tofacitinib","indication_name":"Polyarticular juvenile idiopathic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeljanz","generic_name":"tofacitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes","drug_class":"JAK inhibitor","quality_score":97,"revenue":"1800","mechanism":"Tofacitinib is a JAK inhibitor that prevents phosphorylation and activation of STATs."},{"drug_id":"canakinumab","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ilaris","generic_name":"CANAKINUMAB","company_name":"Novartis Pharms","drug_phase":"marketed","molecular_target":"Interleukin-1 beta","drug_class":"Non-Standardized Plant Allergenic Extract [EPC]","quality_score":59,"revenue":"1369","mechanism":""},{"drug_id":"obinutuzumab","indication_name":"CD20-positive follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gazyva","generic_name":"obinutuzumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":"1200","mechanism":"Gazyva binds to the CD20 antigen on B-lymphocytes, triggering their destruction."},{"drug_id":"in-open-label-phase-treatment-with-tofacitinib","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"In open-label phase: treatment with tofacitinib","generic_name":"in-open-label-phase-treatment-with-tofacitinib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase 1 (JAK1), Janus kinase 3 (JAK3), and tyrosine kinase 2 (TYK2)","drug_class":"Janus kinase inhibitor","quality_score":45,"revenue":"1087","mechanism":""},{"drug_id":"lenvatinib","indication_name":"Follicular thyroid carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lenvima","generic_name":"LENVATINIB","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Proto-oncogene tyrosine-protein kinase receptor Ret","drug_class":"Kinase Inhibitor [EPC]","quality_score":75,"revenue":"1053.0","mechanism":"Lenvima works by blocking the activity of a specific protein called Ret, which is involved in the growth and spread of cancer cells."},{"drug_id":"valsartan","indication_name":"Left ventricular cardiac dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diovan","generic_name":"VALSARTAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Type-1 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":10,"revenue":"447","mechanism":"Diovan works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"tocilizumab-or-sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tocilizumab or sarilumab","generic_name":"tocilizumab-or-sarilumab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"interleukin-6 receptor","drug_class":"monoclonal antibody","quality_score":10,"revenue":"116","mechanism":""},{"drug_id":"fluticasone-propionate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cutivate","generic_name":"FLUTICASONE PROPIONATE","company_name":"Teva Pharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":64,"revenue":"69.0","mechanism":""},{"drug_id":"sulfur-colloid","indication_name":"Imaging reticuloendothelial cells","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sulfur Colloid","company_name":"University of California, San Diego","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":"Technetium Tc 99m Sulfur Colloid is used for imaging by entering lymphatic capillaries, mixing with peritoneal fluid, or being taken up by the reticuloendothelial system."},{"drug_id":"flecainide-acetate","indication_name":"Paroxysmal Supraventricular Tachycardias (PSVT)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLECAINIDE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"flecainide-acetate","indication_name":"Documented Ventricular Arrhythmias","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"FLECAINIDE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":38,"revenue":null,"mechanism":null},{"drug_id":"flumetasone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flucorticin","generic_name":"flumetasone","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"flumetasone","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"diazepam","indication_name":"Status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valium","generic_name":"diazepam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"encainide","indication_name":"Ventricular premature beats","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ENCAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"encainide","quality_score":28,"revenue":null,"mechanism":""},{"drug_id":"diovan","indication_name":"Left ventricular cardiac dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Diovan","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Platelet glycoprotein VI, Type-1 angiotensin II receptor, Angiotensin II receptor (AT-1) type-1","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"fusidic-acid","indication_name":"Folliculitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"ajmaline","indication_name":"Supraventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ajmalin","generic_name":"AJMALINE","company_name":"","drug_phase":"phase_3","molecular_target":"Potassium voltage-gated channel subfamily A member 5","drug_class":"ajmaline","quality_score":36,"revenue":null,"mechanism":"Ajmaline works by blocking potassium channels in the heart to help regulate heart rhythm."},{"drug_id":"ajmaline","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ajmalin","generic_name":"AJMALINE","company_name":"","drug_phase":"phase_3","molecular_target":"Potassium voltage-gated channel subfamily A member 5","drug_class":"ajmaline","quality_score":36,"revenue":null,"mechanism":"Ajmaline works by blocking potassium channels in the heart to help regulate heart rhythm."},{"drug_id":"alclometasone-dipropionate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aclovate","generic_name":"ALCLOMETASONE DIPROPIONATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"keppra","indication_name":"Status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Keppra","company_name":"Masonic Cancer Center, University of Minnesota","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1, Sodium channel protein type 1 subunit alpha, Synaptic vesicle glycoprotein 2A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Polyarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Extended Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tumor-necrosis-factor-inhibitors-tnfi","indication_name":"Juvenile Idiopathic Arthritis with Persistent Oligoarticular Course","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"tumor necrosis factor inhibitors (TNFi)","generic_name":"tumor-necrosis-factor-inhibitors-tnfi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"tumor necrosis factor","drug_class":"biologic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"gentamicin","indication_name":"Folliculitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"ibritumomab-tiuxetan","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zevalin","generic_name":"IBRITUMOMAB TIUXETAN","company_name":"Spectrum Pharms","drug_phase":"discontinued","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Radiotherapeutic Antibody","quality_score":null,"revenue":null,"mechanism":"Zevalin works by binding to CD20 on B cells and delivering a radioactive dose that kills the cells."},{"drug_id":"interferon-alfa-2b","indication_name":"Follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Intron A","generic_name":"INTERFERON ALFA-2B","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Interferon alpha","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"abametapir","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeglyze","generic_name":"ABAMETAPIR","company_name":"Hatchtech","drug_phase":"marketed","molecular_target":"C-C chemokine receptor type 5","drug_class":"","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"chlorothiazide","indication_name":"Hypertension with Left Ventricular Hypertrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diuril","generic_name":"CHLOROTHIAZIDE","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"fludeoxyglucose","indication_name":"left ventricular dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"FLUDEOXYGLUCOSE","company_name":"Downstate Clincl","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive sugar molecule that accumulates in cells with high metabolic activity, allowing for visualization of cancer and other conditions."},{"drug_id":"fludeoxyglucose","indication_name":"coronary artery disease and left ventricular dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"FLUDEOXYGLUCOSE","company_name":"Downstate Clincl","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive sugar molecule that accumulates in cells with high metabolic activity, allowing for visualization of cancer and other conditions."},{"drug_id":"oncovin","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oncovin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"hydrocortisone-succinate","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"fludroxycortide","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cordran","generic_name":"fludroxycortide","company_name":"Aqua Pharms","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"vincristin","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vincristin","company_name":"Arbeitsgemeinschaft medikamentoese Tumortherapie","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"f-18","indication_name":"left ventricular dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"F-18","company_name":"3D Imaging Drug","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive molecule that accumulates in areas of high metabolic activity, allowing for imaging of various conditions."},{"drug_id":"f-18","indication_name":"coronary artery disease and left ventricular dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"F-18","company_name":"3D Imaging Drug","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive molecule that accumulates in areas of high metabolic activity, allowing for imaging of various conditions."},{"drug_id":"depemokimab","indication_name":"status asthmaticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exdensur","generic_name":"DEPEMOKIMAB","company_name":"Glaxosmithkline Llc","drug_phase":"marketed","molecular_target":"Histamine","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Exdensur works by binding to histamine, preventing it from interacting with its receptors and reducing inflammation and airway constriction."},{"drug_id":"distigmine","indication_name":"Difficulty passing urine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ubretid","generic_name":"DISTIGMINE","company_name":"Torii Pharmaceuticals","drug_phase":"marketed","molecular_target":"Acetylcholinesterase","drug_class":"distigmine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bretylium","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bretylium Tosylate","generic_name":"BRETYLIUM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"bretylium","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"bretylium","indication_name":"Prevention of Ventricular Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bretylium Tosylate","generic_name":"BRETYLIUM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"bretylium","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"bretylium","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bretylium Tosylate","generic_name":"BRETYLIUM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"bretylium","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"bretylium","indication_name":"Ventricular fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bretylium Tosylate","generic_name":"BRETYLIUM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"bretylium","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"midazolam-hydrochloride","indication_name":"Status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Versed","generic_name":"Midazolam Hydrochloride","company_name":"Takeda Pharmaceutical Company Limited","drug_phase":"marketed","molecular_target":"GABA A receptor alpha-5/beta-2/gamma-2","drug_class":"Benzodiazepine","quality_score":58,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"amiodarone","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cordarone","generic_name":"AMIODARONE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"sodium channels, potassium channels, calcium channels","drug_class":"Antiarrhythmic","quality_score":69,"revenue":null,"mechanism":"Amiodarone, a class III antiarrhythmic, blocks sodium, potassium, and calcium channels, prolongs cardiac action potentials, and has vasodilatory effects."},{"drug_id":"amiodarone","indication_name":"Prevention of Ventricular Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cordarone","generic_name":"AMIODARONE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"sodium channels, potassium channels, calcium channels","drug_class":"Antiarrhythmic","quality_score":69,"revenue":null,"mechanism":"Amiodarone, a class III antiarrhythmic, blocks sodium, potassium, and calcium channels, prolongs cardiac action potentials, and has vasodilatory effects."},{"drug_id":"amiodarone","indication_name":"Ventricular fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cordarone","generic_name":"AMIODARONE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"sodium channels, potassium channels, calcium channels","drug_class":"Antiarrhythmic","quality_score":69,"revenue":null,"mechanism":"Amiodarone, a class III antiarrhythmic, blocks sodium, potassium, and calcium channels, prolongs cardiac action potentials, and has vasodilatory effects."},{"drug_id":"desoximetasone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Topicort","generic_name":"DESOXIMETASONE","company_name":"Taro","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"enalapril-maleate","indication_name":"Asymptomatic left ventricular systolic dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vasotec","generic_name":"ENALAPRIL MALEATE","company_name":"Azurity","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor","quality_score":67,"revenue":null,"mechanism":"Vasotec works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor."},{"drug_id":"fluocinolone-acetonide","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Derma-Smoothe/Fs","generic_name":"FLUOCINOLONE ACETONIDE","company_name":"Eurofarma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"bleomycin","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blenoxane","generic_name":"BLEOMYCIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Aspartyl/asparaginyl beta-hydroxylase","drug_class":"Cytoprotective Agent","quality_score":62,"revenue":null,"mechanism":"Bleomycin works by binding to DNA and causing strand breaks, which ultimately leads to cell death."},{"drug_id":"bleomycin","indication_name":"Testicular Germ Cell Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blenoxane","generic_name":"BLEOMYCIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Aspartyl/asparaginyl beta-hydroxylase","drug_class":"Cytoprotective Agent","quality_score":62,"revenue":null,"mechanism":"Bleomycin works by binding to DNA and causing strand breaks, which ultimately leads to cell death."},{"drug_id":"acebutolol","indication_name":"Ventricular premature beats","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sectral","generic_name":"ACEBUTOLOL","company_name":"Promius Pharma","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"phenytoin","indication_name":"Status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phenytoin Sodium","generic_name":"PHENYTOIN","company_name":"Viatris","drug_phase":"marketed","molecular_target":"Sodium channel protein type 2 subunit alpha","drug_class":"Anti-epileptic Agent","quality_score":70,"revenue":null,"mechanism":"Phenytoin Sodium works by stabilizing the threshold against hyperexcitability caused by excessive stimulation."},{"drug_id":"clocortolone-pivalate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cloderm","generic_name":"CLOCORTOLONE PIVALATE","company_name":"Legacy Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"disopyramide","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norpace Cr","generic_name":"DISOPYRAMIDE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Antiarrhythmic","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"midazolam","indication_name":"Status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Versed","generic_name":"midazolam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2","drug_class":"Benzodiazepine (short-acting)","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nitrofurantoin","indication_name":"Staphylococcus Saprophyticus Urinary Tract Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Furadantin","generic_name":"NITROFURANTOIN","company_name":"","drug_phase":"marketed","molecular_target":"CDGSH iron-sulfur domain-containing protein 1","drug_class":"Nitrofuran Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Nitrofurantoin is an antibacterial drug."},{"drug_id":"quinidine-sulfate","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quinidine Gluconate","generic_name":"QUINIDINE SULFATE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M2","drug_class":"Antiarrhythmic","quality_score":10,"revenue":null,"mechanism":"Quinidine Gluconate works by blocking the M2 muscarinic acetylcholine receptor, which helps regulate heart rhythm."},{"drug_id":"cortisone-acetate","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"adenosine","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adenocard","generic_name":"ADENOSINE","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Adenosine receptor A3","drug_class":"Adenosine Receptor Agonist [EPC]","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"ulobetasol-propionate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultravate","generic_name":"ulobetasol propionate","company_name":"Ranbaxy","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"ulobetasol propionate","quality_score":10,"revenue":null,"mechanism":"Ultravate works by binding to the glucocorticoid receptor, triggering a cascade of anti-inflammatory effects that reduce skin inflammation."},{"drug_id":"glyceryl-trinitrate","indication_name":"Left ventricular cardiac dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nitroglycerin","generic_name":"glyceryl trinitrate","company_name":"Fougera","drug_phase":"marketed","molecular_target":"guanylate cyclase","drug_class":"Nitrate Vasodilator [EPC]","quality_score":65,"revenue":null,"mechanism":"Nitroglycerin forms nitric oxide, activating guanylate cyclase and increasing cyclic GMP, leading to smooth muscle relaxation and vasodilation."},{"drug_id":"sulbactam","indication_name":"Hospital-acquired bacterial pneumonia caused by acinetobacter baumannii-calcoaceticus complex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"SULBACTAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine beta-lactamase-like protein LACTB, mitochondrial","drug_class":"beta Lactamase Inhibitor","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"sulbactam","indication_name":"Infection caused by carbapenem-resistant acinetobacter baumannii-calcoaceticus complex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"SULBACTAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine beta-lactamase-like protein LACTB, mitochondrial","drug_class":"beta Lactamase Inhibitor","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"sulbactam","indication_name":"Ventilator-associated bacterial pneumonia caused by acinetobacter baumannii-calcoaceticus complex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"SULBACTAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine beta-lactamase-like protein LACTB, mitochondrial","drug_class":"beta Lactamase Inhibitor","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"nitrofurazone","indication_name":"Staphylococcus Saprophyticus Urinary Tract Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Furacin","generic_name":"NITROFURAZONE","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Sterile alpha and TIR motif-containing protein 1","drug_class":"nitrofurazone","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-dipropionate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diprolene","generic_name":"BETAMETHASONE DIPROPIONATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":51,"revenue":null,"mechanism":"Diprolene works by binding to the glucocorticoid receptor in the skin, which reduces inflammation and suppresses the immune system."},{"drug_id":"losartan-potassium","indication_name":"Hypertension with Left Ventricular Hypertrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cozaar","generic_name":"LOSARTAN POTASSIUM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Type-1 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker","quality_score":69,"revenue":null,"mechanism":"Cozaar works by blocking the action of angiotensin II on its receptor, which helps to relax blood vessels and lower blood pressure."},{"drug_id":"cisplatin","indication_name":"Testicular Germ Cell Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Platinol-Aq","generic_name":"cisplatin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Platinum-based Drug [EPC]","quality_score":52,"revenue":null,"mechanism":""},{"drug_id":"captopril","indication_name":"Left ventricular cardiac dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Capozide 25/15","generic_name":"CAPTOPRIL","company_name":"Aarxion Anda Hlding","drug_phase":"marketed","molecular_target":"Renin","drug_class":"Thiazide Diuretic [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"flecainide","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"flecainide","indication_name":"Prevention of Paroxysmal Supraventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-valerate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betamethasone Valerate","generic_name":"BETAMETHASONE VALERATE","company_name":"Fougera Pharms Inc","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"esmolol","indication_name":"Supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brevibloc In Plastic Container","generic_name":"ESMOLOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":63,"revenue":null,"mechanism":"Brevibloc works by blocking the beta-1 adrenergic receptor, which reduces the heart's response to stress and increases heart rate."},{"drug_id":"bendamustine","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treanda","generic_name":"BENDAMUSTINE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Alkylating Drug","quality_score":63,"revenue":null,"mechanism":"Treanda works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow."},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07985631","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07985631","generic_name":"pf-07985631","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"permethrin","indication_name":"Pediculosis Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elimite","generic_name":"PERMETHRIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Pyrethroid [EPC]","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"tetramethrin","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Phthalthrin","generic_name":"TETRAMETHRIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"tetramethrin","quality_score":15,"revenue":null,"mechanism":""},{"drug_id":"permethrin","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elimite","generic_name":"PERMETHRIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Pyrethroid [EPC]","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"permethrin","indication_name":"Pediculosis corporis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elimite","generic_name":"PERMETHRIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Pyrethroid [EPC]","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"fluticasone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flonase","generic_name":"fluticasone propionate","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Inhaled/intranasal corticosteroid","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"tasocitinib","indication_name":"Polyarticular juvenile idiopathic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tasocitinib","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Aurora kinase B, BMP-2-inducible protein kinase, Calcium/calmodulin-dependent protein kinase type 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"buserelin","indication_name":"Induction of final follicular maturation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Receptal","generic_name":"BUSERELIN","company_name":"Sanofi K.K.","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptor","drug_class":"buserelin","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"alprostadil","indication_name":"Aorta Dextratransposition with Intact Ventricular Septum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caverject","generic_name":"ALPROSTADIL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Prostaglandin E2 receptor EP3 subtype","drug_class":"Prostaglandin Analog [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"alprostadil","indication_name":"Congenital atresia of tricuspid valve","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caverject","generic_name":"ALPROSTADIL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Prostaglandin E2 receptor EP3 subtype","drug_class":"Prostaglandin Analog [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"alprostadil","indication_name":"Ebstein's anomaly of tricuspid valve","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caverject","generic_name":"ALPROSTADIL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Prostaglandin E2 receptor EP3 subtype","drug_class":"Prostaglandin Analog [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Staphylococcus Saprophyticus Urinary Tract Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Folliculitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"synarel","indication_name":"Exclusion of other causes of sexual precocity, such as congenital adrenal hyperplasia, testotoxicosis, testicular tumors and/or other autonomous feminizing or masculinizing disorders","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Synarel","generic_name":"Nafarelin Acetate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Gonadotropin-releasing hormone receptors","drug_class":"Gonadotropin-releasing hormone agonists","quality_score":67,"revenue":null,"mechanism":"Gonadotropin-releasing hormone agonist medication"},{"drug_id":"cysticide","indication_name":"Schistosomiasis due to S. Japonicum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cysticide","company_name":"Merck KGaA, Darmstadt, Germany","drug_phase":"phase_1","molecular_target":"Bile salt export pump, Glutathione S-transferase class-mu 26 kDa isozyme, High voltage-activated calcium channel beta subunit CavB1","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"allr3","indication_name":"Relapsed or refractory follicular lymphoma after at least two prior therapies","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allr3","generic_name":"allr3","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"The molecular target of ALLR3 is not specified.","drug_class":"The pharmacological class of ALLR3 is not specified.","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"verapamil-hydrochloride","indication_name":"Control of ventricular rate at rest in patients with chronic atrial flutter and/or atrial fibrillation (in association with digitalis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"verapamil-hydrochloride","indication_name":"Control of ventricular rate during stress in patients with chronic atrial flutter and/or atrial fibrillation (in association with digitalis)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"verapamil-hydrochloride","indication_name":"Prophylaxis of repetitive paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Paroxysmal Supraventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Supraventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Ventricular Arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Ventricular Fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of epilepsy in patients with a history of status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tofacitinib-xeljanz","indication_name":"Polyarticular Juvenile Idiopathic Arthritis (pJIA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tofacitinib (Xeljanz)","generic_name":"tofacitinib-xeljanz","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1 and JAK3","drug_class":"Janus Kinase Inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"verapamil","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isoptin","generic_name":"VERAPAMIL","company_name":"","drug_phase":"marketed","molecular_target":"Voltage-dependent L-type calcium channel subunit alpha-1C","drug_class":"Calcium Channel Blocker","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"verapamil","indication_name":"Prevention of Paroxysmal Supraventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isoptin","generic_name":"VERAPAMIL","company_name":"","drug_phase":"marketed","molecular_target":"Voltage-dependent L-type calcium channel subunit alpha-1C","drug_class":"Calcium Channel Blocker","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"moracizine","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"moracizine","company_name":"","drug_phase":"unknown","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"brevibloc","indication_name":"Supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Brevibloc","company_name":"AOP Orphan Pharmaceuticals AG","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"adriacin","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lorazepam","indication_name":"Status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ativan","generic_name":"lorazepam","company_name":"Generic (originally Wyeth/Pfizer)","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydroxydaunorubicin","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"sotalol","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betapace","generic_name":"sotalol","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Potassium voltage-gated channel subfamily H member 2","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"lignocaine","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lignocaine","company_name":"University of Malaya","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"lignocaine","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lignocaine","company_name":"University of Malaya","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"mexiletine","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mexitil","generic_name":"MEXILETINE","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2B","drug_class":"Antiarrhythmic","quality_score":66,"revenue":null,"mechanism":"Mexitil works by blocking abnormal electrical signals in the heart to restore a normal heartbeat."},{"drug_id":"tazemetostat","indication_name":"Follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tazverik","generic_name":"tazemetostat","company_name":"Epizyme Inc","drug_phase":"marketed","molecular_target":"Polycomb protein EED","drug_class":"Methyltransferase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Tazverik works by blocking the action of the EED protein, which is involved in the regulation of gene expression."},{"drug_id":"prednison","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"kineret","indication_name":"Chronic infantile neurological, cutaneous and articular syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Anakinra","generic_name":"Kineret","company_name":"Biovitrum Ab","drug_phase":"marketed","molecular_target":"Interleukin-1 receptor, type I","drug_class":"Interleukin-1 Receptor Antagonist","quality_score":41,"revenue":null,"mechanism":""},{"drug_id":"lidocaine-hydrochloride","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lignospan Forte","generic_name":"Lidocaine Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"neuronal membrane ionic channels","drug_class":"local anesthetic, amide type","quality_score":68,"revenue":null,"mechanism":"Lidocaine stabilizes neuronal membrane by inhibiting ionic fluxes required for impulse initiation and conduction."},{"drug_id":"lidocaine-hydrochloride","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lignospan Forte","generic_name":"Lidocaine Hydrochloride","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"neuronal membrane ionic channels","drug_class":"local anesthetic, amide type","quality_score":68,"revenue":null,"mechanism":"Lidocaine stabilizes neuronal membrane by inhibiting ionic fluxes required for impulse initiation and conduction."},{"drug_id":"nitrofurantoin-macrocrystalline","indication_name":"Staphylococcus Saprophyticus Urinary Tract Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MACRODANTIN","generic_name":"NITROFURANTOIN, MACROCRYSTALLINE","company_name":"ALMATICA","drug_phase":"marketed","molecular_target":"Mitochondrial pyruvate carrier 2, CDGSH iron-sulfur domain-containing protein 1, Glucose-6-phosphate 1-dehydrogenase","drug_class":"Nitrofuran Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nasonex","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nasonex","company_name":"University of Alberta","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"mosunetuzumab-axgb","indication_name":"Relapsed or refractory follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"LUNSUMIO","generic_name":"MOSUNETUZUMAB-AXGB","company_name":"GENENTECH INC","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":38,"revenue":null,"mechanism":""},{"drug_id":"methylprednisolone","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"methylprednisolone","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"methylprednisolone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"betamethasone-benzoate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betamethasone 17-Benzoate","generic_name":"BETAMETHASONE BENZOATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ethacizine","indication_name":"Supraventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etacizin","generic_name":"ethacizine","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"ethacizine","quality_score":null,"revenue":null,"mechanism":"Etacizin works by blocking potassium channels in the heart, which helps to regulate abnormal heart rhythms."},{"drug_id":"ethacizine","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etacizin","generic_name":"ethacizine","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"ethacizine","quality_score":null,"revenue":null,"mechanism":"Etacizin works by blocking potassium channels in the heart, which helps to regulate abnormal heart rhythms."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"pf-06882961-cohorts-1-and-2","indication_name":"Treatment of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06882961 (Cohorts 1 and 2)","generic_name":"pf-06882961-cohorts-1-and-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"molecular target","drug_class":"pharmacological class","quality_score":10,"revenue":null,"mechanism":"PF-06882961 is a small molecule with a molecular target."},{"drug_id":"hydrocortisone","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"procaine","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isocain","generic_name":"PROCAINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A","drug_class":"Amide Local Anesthetic [EPC]","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"detajmium","indication_name":"Supraventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tachmalcor","generic_name":"detajmium","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"detajmium","quality_score":null,"revenue":null,"mechanism":"Tachmalcor works by stabilizing cardiac ion channels to regulate abnormal heart rhythms."},{"drug_id":"detajmium","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tachmalcor","generic_name":"detajmium","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"detajmium","quality_score":null,"revenue":null,"mechanism":"Tachmalcor works by stabilizing cardiac ion channels to regulate abnormal heart rhythms."},{"drug_id":"aprindine","indication_name":"Supraventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fiboran","generic_name":"APRINDINE","company_name":"","drug_phase":"marketed","molecular_target":"Cytochrome P450 2D6","drug_class":"aprindine","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"aprindine","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fiboran","generic_name":"APRINDINE","company_name":"","drug_phase":"marketed","molecular_target":"Cytochrome P450 2D6","drug_class":"aprindine","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"diltiazem","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cardizem","generic_name":"diltiazem","company_name":"Generic (originally Tanabe Seiyaku)","drug_phase":"marketed","molecular_target":"Voltage-dependent calcium channel gamma-1 subunit, Multidrug resistance protein 1, Solute carrier family 22 member 1","drug_class":"Calcium channel blocker (non-dihydropyridine, benzothiazepine)","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"enalapril","indication_name":"Asymptomatic left ventricular systolic dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vasotec","generic_name":"enalapril","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme, Angiotensin-converting enzyme","drug_class":"ACE inhibitor","quality_score":60,"revenue":null,"mechanism":"ACE inhibitor prodrug that is converted to enalaprilat, blocking angiotensin-converting enzyme to lower blood pressure."},{"drug_id":"landiolol","indication_name":"Hemodynamically unstable ventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onoact","generic_name":"LANDIOLOL","company_name":"Aop Hlth Us","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"landiolol","quality_score":37,"revenue":null,"mechanism":"Onoact works by blocking the beta-1 adrenergic receptor, which helps to slow down abnormal heart rhythms."},{"drug_id":"landiolol","indication_name":"Supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onoact","generic_name":"LANDIOLOL","company_name":"Aop Hlth Us","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"landiolol","quality_score":37,"revenue":null,"mechanism":"Onoact works by blocking the beta-1 adrenergic receptor, which helps to slow down abnormal heart rhythms."},{"drug_id":"landiolol","indication_name":"Ventricular fibrillation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Onoact","generic_name":"LANDIOLOL","company_name":"Aop Hlth Us","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"landiolol","quality_score":37,"revenue":null,"mechanism":"Onoact works by blocking the beta-1 adrenergic receptor, which helps to slow down abnormal heart rhythms."},{"drug_id":"triamcinolone","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"flixotide","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Flixotide","company_name":"Mundipharma Research Limited","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"levetiracetam","indication_name":"Status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keppra","generic_name":"levetiracetam","company_name":"Generic (originally UCB Pharma)","drug_phase":"marketed","molecular_target":"Synaptic vesicle protein SV2A","drug_class":"Antiepileptic agent","quality_score":10,"revenue":null,"mechanism":"Levetiracetam binds to synaptic vesicle protein SV2A, potentially regulating vesicle exocytosis."},{"drug_id":"fluticason","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluticason","company_name":"Creighton University","drug_phase":"marketed","molecular_target":"Cytosolic phospholipase A2, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"hydrochlorothiazide","indication_name":"Hypertension with Left Ventricular Hypertrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Microzide","generic_name":"hydrochlorothiazide","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"ACE","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Lisinopril inhibits ACE, reducing angiotensin II and aldosterone, leading to lower blood pressure."},{"drug_id":"prednisone","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"losartan","indication_name":"Hypertension with Left Ventricular Hypertrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cozaar","generic_name":"losartan","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"AT1 receptor","drug_class":"ARB (Angiotensin II receptor blocker)","quality_score":65,"revenue":null,"mechanism":"Losartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 receptor."},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"propranolol","indication_name":"Life-Threatening Ventricular Tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inderal","generic_name":"propranolol","company_name":"Generic (originally ICI/AstraZeneca)","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2","drug_class":"Non-selective beta-blocker","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"propranolol","indication_name":"Supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inderal","generic_name":"propranolol","company_name":"Generic (originally ICI/AstraZeneca)","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2","drug_class":"Non-selective beta-blocker","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"mesna","indication_name":"Testicular Germ Cell Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mesnex","generic_name":"MESNA","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"mesna","quality_score":70,"revenue":null,"mechanism":"Mesnex works by binding to and neutralizing acrolein, a toxic byproduct of chemotherapy that causes hemorrhagic cystitis."},{"drug_id":"spinosad","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Natroba","generic_name":"SPINOSAD","company_name":"Cipher","drug_phase":"marketed","molecular_target":"","drug_class":"Pediculicide [EPC]","quality_score":40,"revenue":null,"mechanism":"Natroba works by activating glutamate-gated chloride channels in the nervous system of lice, leading to an influx of chloride ions and eventual death."},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"chlorambucil","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leukeran","generic_name":"CHLORAMBUCIL","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Cathepsin D","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Leukeran works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"malathion","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ovide","generic_name":"MALATHION","company_name":"Taro","drug_phase":"marketed","molecular_target":"Melatonin receptor type 1A","drug_class":"Cholinesterase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"amikacin","indication_name":"Diverticulitis of gastrointestinal tract","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"triamcinolone-hexacetonide","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aristospan","generic_name":"TRIAMCINOLONE HEXACETONIDE","company_name":"Ethypharm","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"fluocinonide","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lidex","generic_name":"FLUOCINONIDE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"carvedilol","indication_name":"Left ventricular cardiac dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Coreg","generic_name":"CARVEDILOL","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"alpha-Adrenergic Blocker [EPC]","quality_score":70,"revenue":null,"mechanism":"Coreg works by blocking the effects of the hormone epinephrine on the heart, reducing its workload and improving its function."},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"fosphenytoin","indication_name":"Status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cerebyx","generic_name":"FOSPHENYTOIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"Anti-epileptic Agent","quality_score":80,"revenue":null,"mechanism":"Cerebyx works by stabilizing the inactivated state of sodium channels, preventing the rapid firing of neurons that can lead to seizures."},{"drug_id":"vincristine-sulfate-pfs","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oncovin","generic_name":"Vincristine Sulfate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1","drug_class":"Vinca Alkaloid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"halcinonide","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Halog","generic_name":"HALCINONIDE","company_name":"Sun Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"dexmedetomidine-hydrochloride","indication_name":"Sedation of non-intubated patients in the intensive care unit (ICU) or in a hospital setting receiving mechanical ventilation.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexmedetomidine Hydrochloride","generic_name":"dexmedetomidine-hydrochloride","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor","drug_class":"dexmedetomidine","quality_score":80,"revenue":null,"mechanism":"Dexmedetomidine Hydrochloride is a relatively selective centrally acting alpha 2 -adrenergic agonist with sedative properties."},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"norpace","indication_name":"Documented ventricular arrhythmias","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norpace Cr","generic_name":"Disopyramide Phosphate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"G protein-activated inward rectifier potassium channel 4","drug_class":"High Risk QT Prolonging Agents","quality_score":10,"revenue":null,"mechanism":"Norpace is a sodium channel blocker and a Class 1a anti-arrhythmic agent."},{"drug_id":"norpace","indication_name":"Sustained ventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norpace Cr","generic_name":"Disopyramide Phosphate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"G protein-activated inward rectifier potassium channel 4","drug_class":"High Risk QT Prolonging Agents","quality_score":10,"revenue":null,"mechanism":"Norpace is a sodium channel blocker and a Class 1a anti-arrhythmic agent."},{"drug_id":"norpace","indication_name":"Life-threatening ventricular arrhythmias","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norpace Cr","generic_name":"Disopyramide Phosphate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"G protein-activated inward rectifier potassium channel 4","drug_class":"High Risk QT Prolonging Agents","quality_score":10,"revenue":null,"mechanism":"Norpace is a sodium channel blocker and a Class 1a anti-arrhythmic agent."},{"drug_id":"inavolisib","indication_name":"Relapsed or refractory advanced follicular lymphoma (FL) after at least two prior lines of therapy for whom MAb-based therapy has failed","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"inavolisib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA)","drug_class":"Kinase Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Inavolisib is a PI3K inhibitor with degradative activity against PI3Kα."},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"cefpodoxime-proxetil","indication_name":"Staphylococcus Saprophyticus Urinary Tract Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vantin","generic_name":"CEFPODOXIME PROXETIL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"golimumab","indication_name":"Polyarticular juvenile idiopathic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Simponi","generic_name":"GOLIMUMAB","company_name":"Centocor Ortho Biotech Inc","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"Tumor Necrosis Factor Blocker [EPC]","quality_score":60,"revenue":null,"mechanism":"Simponi works by binding to tumor necrosis factor, preventing it from interacting with its receptors and thereby reducing inflammation."},{"drug_id":"allopurinol","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aloprim","generic_name":"ALLOPURINOL","company_name":"Casper Pharma Llc","drug_phase":"marketed","molecular_target":"Xanthine dehydrogenase/oxidase","drug_class":"Xanthine Oxidase Inhibitor [EPC]","quality_score":70,"revenue":null,"mechanism":"Aloprim works by inhibiting the enzyme xanthine oxidase, which is responsible for producing uric acid in the body."},{"drug_id":"enalaprilat","indication_name":"Asymptomatic left ventricular systolic dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vasotec","generic_name":"ENALAPRILAT","company_name":"Biovail Labs Intl","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"enalaprilat","quality_score":75,"revenue":null,"mechanism":"Vasotec works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor."},{"drug_id":"doxepin","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zonalon","generic_name":"DOXEPIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Tricyclic Antidepressant","quality_score":80,"revenue":null,"mechanism":"Zonalon works by blocking histamine H1 receptors in the brain, which helps to reduce anxiety and itching, and improve mood."},{"drug_id":"prednicarbate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dermatop","generic_name":"PREDNICARBATE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tisagenlecleucel","indication_name":"DLBCL arising from follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"tisagenlecleucel","indication_name":"relapsed or refractory follicular lymphoma (FL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"tisagenlecleucel","indication_name":"relapsed or refractory (r/r) follicular lymphoma (FL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kymriah","generic_name":"TISAGENLECLEUCEL","company_name":"Novartis Pharmaceuticals Corporation","drug_phase":"marketed","molecular_target":"","drug_class":"CD19-directed Chimeric Antigen Receptor [EPC]","quality_score":50,"revenue":null,"mechanism":"Kymriah modifies a patient's T-cells to recognize and attack cancer cells expressing the CD19 protein."},{"drug_id":"mosunetuzumab","indication_name":"Relapsed or refractory follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lunsumio","generic_name":"MOSUNETUZUMAB","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":52,"revenue":null,"mechanism":"Lunsumio works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction."},{"drug_id":"vincristine","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oncovin","generic_name":"vincristine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1","drug_class":"Vinca Alkaloid","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"durlobactam","indication_name":"Hospital-acquired bacterial pneumonia caused by acinetobacter baumannii-calcoaceticus complex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xacduro (Copackaged)","generic_name":"DURLOBACTAM","company_name":"Entasis Therap","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":45,"revenue":null,"mechanism":"Xacduro works by binding to and inhibiting bacterial beta-lactamases, allowing antibiotics to effectively kill bacteria."},{"drug_id":"durlobactam","indication_name":"Infection caused by carbapenem-resistant acinetobacter baumannii-calcoaceticus complex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xacduro (Copackaged)","generic_name":"DURLOBACTAM","company_name":"Entasis Therap","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":45,"revenue":null,"mechanism":"Xacduro works by binding to and inhibiting bacterial beta-lactamases, allowing antibiotics to effectively kill bacteria."},{"drug_id":"durlobactam","indication_name":"Ventilator-associated bacterial pneumonia caused by acinetobacter baumannii-calcoaceticus complex","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xacduro (Copackaged)","generic_name":"DURLOBACTAM","company_name":"Entasis Therap","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":45,"revenue":null,"mechanism":"Xacduro works by binding to and inhibiting bacterial beta-lactamases, allowing antibiotics to effectively kill bacteria."},{"drug_id":"ruxience","indication_name":"Follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"Rituximab-Pvvr","company_name":"Roche","drug_phase":"marketed","molecular_target":"CD20 antigen on pre-B and mature B-lymphocytes","drug_class":"Monoclonal antibody","quality_score":10,"revenue":null,"mechanism":"Monoclonal antibody targeting CD20 on B-lymphocytes, mediating cell lysis via CDC and ADCC."},{"drug_id":"chorionic-gonadotrophin","indication_name":"Induction of final follicular maturation and luteinization","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Choriogonadotropin","generic_name":"chorionic gonadotrophin","company_name":"Ferring","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"rituximab","indication_name":"Follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mabthera","generic_name":"rituximab","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction."},{"drug_id":"prajmalium","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prajmaline","generic_name":"PRAJMALIUM","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"prajmalium","quality_score":null,"revenue":null,"mechanism":"Prajmaline works by blocking sodium channels in the heart, which helps to regulate abnormal heart rhythms."},{"drug_id":"liposomal-doxorubicin","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"isoprenaline","indication_name":"Atrioventricular block","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isuprel","generic_name":"isoprenaline","company_name":"","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta-Adrenergic Agonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"mometasone-furoate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elocon","generic_name":"MOMETASONE FUROATE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Progesterone receptor","drug_class":"Corticosteroid","quality_score":75,"revenue":null,"mechanism":"Elocon works by binding to the progesterone receptor, which reduces inflammation and immune response in the body."},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe lichen simplex chronicus in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"tocilizumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis (PJIA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Roactemra","generic_name":"tocilizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Interleukin-6 receptor","drug_class":"Interleukin-6 Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation."},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"adenosine-triphosphate","indication_name":"Supraventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Triphosphoric Acid Adenosine Ester","generic_name":"ADENOSINE TRIPHOSPHATE","company_name":"","drug_phase":"marketed","molecular_target":"P2X purinoceptor 3","drug_class":"Vitamin C [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"ganciclovir","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytovene","generic_name":"GANCICLOVIR","company_name":"Roche Palo","drug_phase":"marketed","molecular_target":"Metabotropic glutamate receptor 1","drug_class":"Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"GANCICLOVIR works by inhibiting the DNA polymerase enzyme of cytomegalovirus, preventing viral replication."},{"drug_id":"amobarbital","indication_name":"Status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amobarbitone","generic_name":"AMOBARBITAL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"amobarbital","quality_score":28,"revenue":null,"mechanism":""},{"drug_id":"pentobarbital","indication_name":"Status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nembutal Sodium","generic_name":"PENTOBARBITAL","company_name":"Oak Pharms","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"pentobarbital","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"diflorasone-diacetate","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Psorcon","generic_name":"DIFLORASONE DIACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":39,"revenue":null,"mechanism":""},{"drug_id":"probenecid","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Col-Probenecid","generic_name":"probenecid","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 9","drug_class":"probenecid","quality_score":10,"revenue":null,"mechanism":"ORLYNVAH combines sulopenem etzadroxil, a penem antibacterial, with probenecid to increase sulopenem's plasma concentration by inhibiting its renal clearance."},{"drug_id":"anakinra","indication_name":"Chronic infantile neurological, cutaneous and articular syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kineret","generic_name":"ANAKINRA","company_name":"Biovitrum Ab","drug_phase":"marketed","molecular_target":"Interleukin-1 receptor, type I","drug_class":"Interleukin-1 Receptor Antagonist [EPC]","quality_score":70,"revenue":null,"mechanism":"Kineret blocks the action of interleukin-1, a protein that promotes inflammation."},{"drug_id":"norfloxacin","indication_name":"Staphylococcus Saprophyticus Urinary Tract Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Staphylococcus Saprophyticus Urinary Tract Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"amcinonide","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclocort","generic_name":"AMCINONIDE","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"xeljanz-xr","indication_name":"Polyarticular juvenile idiopathic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeljanz","generic_name":"Tofacitinib Citrate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes","drug_class":"JAK inhibitor","quality_score":72,"revenue":null,"mechanism":"Tofacitinib inhibits Janus kinase enzymes to prevent STAT phosphorylation and activation."},{"drug_id":"methoxamine","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Methoxamin","generic_name":"METHOXAMINE","company_name":"GSK","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor","drug_class":"methoxamine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"minocycline","indication_name":"Ureaplasma Urealyticum Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Minocycline Hydrochloride","generic_name":"MINOCYCLINE","company_name":"Rempex","drug_phase":"marketed","molecular_target":"","drug_class":"Tetracycline-class Drug","quality_score":75,"revenue":null,"mechanism":"MINOCYCLINE works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"betamethasone","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"betamethasone","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"betamethasone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"doxorubicin","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"ciprofloxacin","indication_name":"Staphylococcus Saprophyticus Urinary Tract Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ifosfamide","indication_name":"Testicular Germ Cell Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ifex","generic_name":"IFOSFAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":70,"revenue":null,"mechanism":"Ifosfamide is activated by liver enzymes to form cytotoxic compounds that cause DNA crosslinks, leading to cell death."},{"drug_id":"ramipril","indication_name":"Left ventricular cardiac dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Altace","generic_name":"RAMIPRIL","company_name":"King Pfizer","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Altace works by blocking the action of angiotensin-converting enzyme, a key player in the renin-angiotensin-aldosterone system that regulates blood pressure."},{"drug_id":"chembl-chembl3414621","indication_name":"Follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tazverik","generic_name":"TAZEMETOSTAT","company_name":"Epizyme Inc","drug_phase":"marketed","molecular_target":"Polycomb protein EED","drug_class":"Methyltransferase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Tazverik works by blocking the action of an enzyme called EED, which is involved in the production of proteins that promote cancer growth."},{"drug_id":"copanlisib","indication_name":"Follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aliqopa","generic_name":"COPANLISIB","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform","drug_class":"Kinase Inhibitor","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"duvelisib","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Copiktra","generic_name":"DUVELISIB","company_name":"Secura","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Copiktra works by blocking an enzyme that helps cancer cells grow and multiply."},{"drug_id":"dilantin","indication_name":"Status epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dilantin","generic_name":"Phenytoin Sodium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3","drug_class":"phenytoin","quality_score":80,"revenue":null,"mechanism":"Phenytoin exerts its therapeutic effect by voltage-dependent blockade of membrane sodium channels."},{"drug_id":"ifo","indication_name":"Testicular Germ Cell Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"IFO","company_name":"Italian Sarcoma Group","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Alkylating Agent","quality_score":null,"revenue":null,"mechanism":"Ifosfamide is an alkylating agent that cross-links DNA, preventing cell replication and inducing apoptosis."},{"drug_id":"levofloxacin","indication_name":"Staphylococcus Saprophyticus Urinary Tract Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Levaquin","generic_name":"levofloxacin","company_name":"Generic (originally Daiichi Sankyo/J&J)","drug_phase":"marketed","molecular_target":"CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2","drug_class":"Fluoroquinolone Antibacterial [EPC]","quality_score":65,"revenue":null,"mechanism":"Levofloxacin is a fluoroquinolone antibacterial agent."},{"drug_id":"cortisol","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cortisol","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bendamustin","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bendamustin","company_name":"Meir Medical Center","drug_phase":"marketed","molecular_target":"Histone deacetylase 1, Histone deacetylase 10, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"hydroxydaunomycin","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lenali","indication_name":"Follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lenali","company_name":"Singapore General Hospital","drug_phase":"marketed","molecular_target":"Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tazverik","indication_name":"Follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Tazverik","company_name":"Edwin Posadas, MD","drug_phase":"discontinued","molecular_target":"Polycomb protein EED, Histone-lysine N-methyltransferase EZH1, Histone-lysine N-methyltransferase EZH2","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"pyrethrins","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pyrethrins","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pyrethrins","indication_name":"Pediculosis corporis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pyrethrins","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adenosin","indication_name":"Paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adenosin","company_name":"University of Roma La Sapienza","drug_phase":"marketed","molecular_target":"Phosphatidylinositol 4-kinase type 2-alpha, Phosphatidylinositol 4-kinase type 2-beta, Adenosine kinase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"isophosphamide","indication_name":"Testicular Germ Cell Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Isophosphamide","company_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","drug_phase":"phase_2","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"gazyvaro","indication_name":"CD20-positive follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Gazyvaro","company_name":"Incyte Corporation","drug_phase":"phase_1","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lidocain","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lidocain","company_name":"Bayer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lidocain","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lidocain","company_name":"Bayer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"simponi","indication_name":"Polyarticular juvenile idiopathic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Simponi","company_name":"Alvotech Swiss AG","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nitroglycerine","indication_name":"Left ventricular cardiac dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"nitroglycerine","company_name":"University Hospital, Ghent","drug_phase":"marketed","molecular_target":"Atrial natriuretic peptide receptor 1, Soluble guanylate cyclase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Staphylococcus Saprophyticus Urinary Tract Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zevalin","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zevalin","company_name":"Spectrum Pharmaceuticals, Inc","drug_phase":"discontinued","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"adriamycin","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prostavasin","indication_name":"Aorta Dextratransposition with Intact Ventricular Septum","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prostavasin","company_name":"Hannover Medical School","drug_phase":"phase_2","molecular_target":"Cation channel sperm-associated protein 1, Cation channel sperm-associated protein 2, Cation channel sperm-associated protein 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prostavasin","indication_name":"Congenital atresia of tricuspid valve","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prostavasin","company_name":"Hannover Medical School","drug_phase":"phase_2","molecular_target":"Cation channel sperm-associated protein 1, Cation channel sperm-associated protein 2, Cation channel sperm-associated protein 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prostavasin","indication_name":"Ebstein's anomaly of tricuspid valve","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prostavasin","company_name":"Hannover Medical School","drug_phase":"phase_2","molecular_target":"Cation channel sperm-associated protein 1, Cation channel sperm-associated protein 2, Cation channel sperm-associated protein 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"revlimid","indication_name":"Follicular lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Revlimid","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Bromodomain-containing protein 4, Protein cereblon, Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Articular gout","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"mavik","indication_name":"Left ventricular cardiac dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mavik","company_name":"Dr. Reddy's Laboratories Limited","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xylocain","indication_name":"Pediculosis capitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"xylocain","company_name":"Saint-Joseph University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xylocain","indication_name":"Ventricular arrhythmia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"xylocain","company_name":"Saint-Joseph University","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"zydelig","indication_name":"Follicular non-Hodgkin's lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zydelig","company_name":"University of Maryland, Baltimore","drug_phase":"marketed","molecular_target":"DNA-dependent protein kinase catalytic subunit, Phosphatidylinositol 3-kinase catalytic subunit type 3, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ifosfamid","indication_name":"Testicular Germ Cell Tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ifosfamid","company_name":"Polish Lymphoma Research Group","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"minocyclin","indication_name":"Ureaplasma Urealyticum Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Minocyclin","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"tofa","indication_name":"Polyarticular juvenile idiopathic arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOFA","company_name":"","drug_phase":"marketed","molecular_target":"Aurora kinase B, BMP-2-inducible protein kinase, Calcium/calmodulin-dependent protein kinase type 1","drug_class":"","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"mometasone","indication_name":"Lichen simplex chronicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MOMETASONE","company_name":"","drug_phase":"discontinued","molecular_target":"Multidrug resistance protein 1, Glucocorticoid receptor, Progesterone receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"12.1 Mechanism of Action Mometasone furoate nasal spray is a corticosteroid demonstrating potent anti-inflammatory properties. The precise mechanism of corticosteroid action on allergic rhinitis is not known. Corticosteroids have been shown to have a wide range of effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation. In two clinical studies utilizing nasal antigen challenge, mometasone furoate nasal spray decreased some markers of the early- and late-phase allergic response. These observations included decreases (vs. placebo) in histamine and eosinophil cationic protein levels, and reductions (vs. baseline) in eosinophils, neutrophils, and epithelial cell adhesion proteins. The clinical significance of these findings is not known. The effect of mometasone furoate nasal spray on nasal mucosa following 12 months of treatment was examined in 46 patients with allergic rhinitis. There was no evidence of atrophy and there was a marked reduction in intraepithelial eosinophilia and inflammatory cell infiltration (e.g., eosinophils, lymphocytes, monocytes, neutrophils, and plasma cells)."},{"drug_id":"various","indication_name":"Platonicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Various","generic_name":"various","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Antibiotic","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"prednisone","indication_name":"Herpes zoster ophthalmicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"tazemetostat","indication_name":"Relapsed or Refractory Follicular Lymphoma with EZH2 Mutation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tazverik","generic_name":"tazemetostat","company_name":"Epizyme Inc","drug_phase":"marketed","molecular_target":"Polycomb protein EED","drug_class":"Methyltransferase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Tazverik works by blocking the action of the EED protein, which is involved in the regulation of gene expression."},{"drug_id":"tazemetostat","indication_name":"Relapsed or Refractory Follicular Lymphoma without Satisfactory Alternatives","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tazverik","generic_name":"tazemetostat","company_name":"Epizyme Inc","drug_phase":"marketed","molecular_target":"Polycomb protein EED","drug_class":"Methyltransferase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Tazverik works by blocking the action of the EED protein, which is involved in the regulation of gene expression."},{"drug_id":"zanubrutinib","indication_name":"Follicular lymphoma (FL)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brukinsa","generic_name":"ZANUBRUTINIB","company_name":"BeiGene","drug_phase":"marketed","molecular_target":"","drug_class":"Kinase Inhibitor [EPC]","quality_score":33,"revenue":null,"mechanism":null},{"drug_id":"verapamil-hydrochloride","indication_name":"Prophylaxis of paroxysmal supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"flecainide","indication_name":"Paroxysmal Supraventricular Tachycardias (PSVT)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"flecainide","indication_name":"Documented Ventricular Arrhythmias","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tambocor","generic_name":"FLECAINIDE","company_name":"","drug_phase":"marketed","molecular_target":"Potassium voltage-gated channel subfamily H member 2","drug_class":"Antiarrhythmic","quality_score":59,"revenue":null,"mechanism":""},{"drug_id":"esmolol","indication_name":"Control of ventricular rate in supraventricular tachycardia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brevibloc In Plastic Container","generic_name":"ESMOLOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":63,"revenue":null,"mechanism":"Brevibloc works by blocking the beta-1 adrenergic receptor, which reduces the heart's response to stress and increases heart rate."},{"drug_id":"ether","indication_name":"Relief of difficulty sleeping","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ETHER","company_name":"","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Standardized Chemical Allergen [EPC]","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"enalapril-maleate","indication_name":"Asymptomatic Left Ventricular Dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vasotec","generic_name":"ENALAPRIL MALEATE","company_name":"Azurity","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor","quality_score":67,"revenue":null,"mechanism":"Vasotec works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor."},{"drug_id":"mexiletine","indication_name":"Ventricular Arrhythmias","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mexitil","generic_name":"MEXILETINE","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2B","drug_class":"Antiarrhythmic","quality_score":66,"revenue":null,"mechanism":"Mexitil works by blocking abnormal electrical signals in the heart to restore a normal heartbeat."},{"drug_id":"cisatracurium-besylate","indication_name":"Mechanical ventilation in the ICU in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nimbex","generic_name":"Cisatracurium Besylate","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Acetylcholine receptor","drug_class":"Nondepolarizing Neuromuscular Blocker","quality_score":10,"revenue":null,"mechanism":"Nimbex works by blocking the action of acetylcholine at the neuromuscular junction, preventing muscle contraction."},{"drug_id":"dexamethasone-phosphate","indication_name":"Herpes zoster ophthalmicus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"chlorella","indication_name":"Difficulty losing weight","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Chlorella","company_name":"Cardinal Tien Hospital","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"fosphenytoin","indication_name":"Generalized Tonic-Clonic Status Epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cerebyx","generic_name":"FOSPHENYTOIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"Anti-epileptic Agent","quality_score":80,"revenue":null,"mechanism":"Cerebyx works by stabilizing the inactivated state of sodium channels, preventing the rapid firing of neurons that can lead to seizures."},{"drug_id":"dactinomycin","indication_name":"Metastatic Nonseminomatous Testicular Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cosmegen","generic_name":"DACTINOMYCIN","company_name":"Recordati","drug_phase":"marketed","molecular_target":"DNA","drug_class":"Actinomycin [EPC]","quality_score":65,"revenue":null,"mechanism":"Dactinomycin binds DNA and inhibits RNA synthesis, demonstrating cytotoxic activity in cancer models."},{"drug_id":"chembl-chembl1201576","indication_name":"Relapsed or Refractory Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RITUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1201576","indication_name":"Previously Untreated Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RITUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1201576","indication_name":"Non-Progressing Follicular Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"RITUXIMAB","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"mexiletine-hydrochloride","indication_name":"Ventricular Arrhythmias","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MEXILETINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"sodium channels","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Mexiletine, an oral antiarrhythmic, reduces ventricular arrhythmias by inhibiting sodium currents and altering refractory periods."},{"drug_id":"nsaids-ibubrofen-aspirin","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NSAIDs \"ibubrofen,Aspirin\"","company_name":"Assiut University","drug_phase":"marketed","molecular_target":"","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"midazolam-injection","indication_name":"Status Epilepticus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Midazolam injection","company_name":"Abliva AB","drug_phase":"marketed","molecular_target":"","drug_class":"Benzodiazepine [EPC]","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"xzp-5610-tablet-for-part-c2","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"XZP-5610 Tablet for \"Part C2\"","company_name":"Xuanzhu Biopharmaceutical Co., Ltd.","drug_phase":"marketed","molecular_target":"","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl44657","indication_name":"Refractory Testicular Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ETOPOSIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Topoisomerase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl1200641","indication_name":"Mechanical Ventilation in ICU","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CISATRACURIUM BESYLATE","company_name":"","drug_phase":"marketed","molecular_target":"cholinergic receptors","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Cisatracurium besylate blocks neuromuscular transmission by competitively binding to cholinergic receptors and antagonizing acetylcholine."},{"drug_id":"multiple-visit-corticosteroid-paste","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Multiple-Visit-\"Corticosteroid Paste\"","company_name":"Istanbul Medipol University Hospital","drug_phase":"marketed","molecular_target":"cyclooxygenase (COX-1 and COX-2)","drug_class":"Nonsteroidal Anti-inflammatory Drug [EPC]","quality_score":45,"revenue":null,"mechanism":"Naproxen reduces pain, inflammation, and fever by inhibiting prostaglandin synthesis through COX-1 and COX-2 inhibition."},{"drug_id":"ifosfamide","indication_name":"Third-line chemotherapy for germ cell testicular cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ifex","generic_name":"IFOSFAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":70,"revenue":null,"mechanism":"Ifosfamide is activated by liver enzymes to form cytotoxic compounds that cause DNA crosslinks, leading to cell death."},{"drug_id":"chembl-chembl11359","indication_name":"Metastatic Testicular Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CISPLATIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Platinum-based Drug [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl526","indication_name":"ICU Sedation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PROPOFOL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"General Anesthetic [EPC]","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"sarilumab","indication_name":"Polyarticular Juvenile Idiopathic Arthritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SARILUMAB","company_name":"","drug_phase":"marketed","molecular_target":"IL-6 receptors (sIL-6R and mIL-6R)","drug_class":"Interleukin-6 Receptor Antagonist [EPC]","quality_score":60,"revenue":null,"mechanism":"Sarilumab inhibits IL-6 signaling by binding to both soluble and membrane-bound IL-6 receptors."},{"drug_id":"doxepin-hydrochloride","indication_name":"Insomnia with sleep maintenance difficulty","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXEPIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"H1 receptor","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Doxepin may help maintain sleep by blocking H1 receptors."},{"drug_id":"sulfur-colloid","indication_name":"Imaging reticuloendothelial cells","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sulfur Colloid","company_name":"University of California, San Diego","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":"Technetium Tc 99m Sulfur Colloid is used for imaging by entering lymphatic capillaries, mixing with peritoneal fluid, or being taken up by the reticuloendothelial system."}],"pipeline":[{"drug_id":"oral-anticoagulant","indication_name":"Left ventricular thrombus","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oral Anticoagulant","generic_name":"oral-anticoagulant","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Factor Xa (coagulation Factor X, activated form)","drug_class":"Direct oral anticoagulant (DOAC); Factor Xa inhibitor","quality_score":31,"revenue":null,"mechanism":"Inhibits Factor Xa to block the intrinsic and extrinsic coagulation pathways, preventing thrombin generation and clot formation."}],"offLabel":[],"totalMarketed":830,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT06289075","title":"PrognostICate- Study:Prognostication of ICU- and Ventilator- Days Over the Next Years Until 2040","phase":"","overall_status":"RECRUITING","enrollment_count":10000000,"lead_sponsor_name":"University Hospital of Cologne","has_results":false},{"nct_id":"NCT05198492","title":"Short- and Long-term Health Effects of Air Pollution in Poland","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8300000,"lead_sponsor_name":"Medical University of Bialystok","has_results":false},{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT00622557","title":"General Surgical Outcomes Quality Improvement Database (UH-SOCRATES)","phase":"","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"University Hospitals Cleveland Medical Center","has_results":false},{"nct_id":"NCT04024865","title":"Domperidone and Risk of Serious Cardiac Events in Postpartum Women","phase":"","overall_status":"COMPLETED","enrollment_count":184929,"lead_sponsor_name":"Canadian Network for Observational Drug Effect Studies, CNODES","has_results":false},{"nct_id":"NCT05745129","title":"Applying Artificial Intelligence in Developing Personalized and Sustainable Healthcare for Spinal Disorders","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":165000,"lead_sponsor_name":"Oslo Metropolitan University","has_results":false},{"nct_id":"NCT04541498","title":"Impact of Air Pollution and Climate Changes on the Epidemiology of Cardiovascular Disease","phase":"","overall_status":"COMPLETED","enrollment_count":150000,"lead_sponsor_name":"Medical University of Bialystok","has_results":false},{"nct_id":"NCT05150548","title":"Predictive Time-to-Event Model for Major Medical Complications After Colectomy","phase":"","overall_status":"UNKNOWN","enrollment_count":130000,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT02743481","title":"Early Life Exposures in Agriculture","phase":"","overall_status":"COMPLETED","enrollment_count":60000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05893095","title":"Evaluation of Laparoscopic Peritoneal Lavage for Perforated Diverticulitis: A National Registry - Based Study","phase":"","overall_status":"COMPLETED","enrollment_count":52863,"lead_sponsor_name":"Uppsala University Hospital","has_results":false},{"nct_id":"NCT04353232","title":"Impact of Lifetime Exposure to Air and Noise Pollution on Cardiovascular Disease and Mortality - the AIRCARD Study.","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33723,"lead_sponsor_name":"Odense University Hospital","has_results":false},{"nct_id":"NCT07515859","title":"Risk Stratification of Cancer Therapy-Related Cardiac Dysfunction Using AI-Enhanced Electrocardiography","phase":"","overall_status":"COMPLETED","enrollment_count":31486,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT05140265","title":"De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"University of New Mexico","has_results":false},{"nct_id":"NCT06955195","title":"Youth-for-Youth Mental Wellness Care and Action","phase":"NA","overall_status":"RECRUITING","enrollment_count":18000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT04458220","title":"Research on Early Warning and Solution System of Difficult Airway in Perioperative Period Based on Artificial Intelligence","phase":"","overall_status":"UNKNOWN","enrollment_count":16000,"lead_sponsor_name":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","has_results":false},{"nct_id":"NCT06763549","title":"COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":15000,"lead_sponsor_name":"Peerbridge Health, Inc","has_results":false},{"nct_id":"NCT05162560","title":"Incidence and Outcome of Acute Diverticulitis in Finland","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"Kuopio University Hospital","has_results":false},{"nct_id":"NCT06607471","title":"Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Scientific Institute San Raffaele","has_results":false},{"nct_id":"NCT07263204","title":"AI-Enabled Diagnosis and Prognosis of Hypertrophic Cardiomyopathy","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05117970","title":"Artificial Intelligence-assisted Diagnosis and Prognostication in Low Ejection Fraction Using Electrocardiograms","phase":"NA","overall_status":"COMPLETED","enrollment_count":13631,"lead_sponsor_name":"National Defense Medical Center, Taiwan","has_results":false},{"nct_id":"NCT01584141","title":"Study of Lymphoma in Asia","phase":"","overall_status":"COMPLETED","enrollment_count":13433,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06968533","title":"ECG Low Ejection Fraction Detection and Guiding in AI Navigated Treatment Era","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":13350,"lead_sponsor_name":"National Defense Medical Center, Taiwan","has_results":false},{"nct_id":"NCT06885216","title":"Outcomes After Surgery for Degenerative Cervical Radiculopathy in Patients with Concurrent Headache","phase":"","overall_status":"COMPLETED","enrollment_count":12000,"lead_sponsor_name":"University Hospital of North Norway","has_results":false},{"nct_id":"NCT05867407","title":"A Multicenter Pragmatic Implementation Study of ECG-AI-Based Clinical Decision Support Software to Identify Low LVEF","phase":"NA","overall_status":"TERMINATED","enrollment_count":11610,"lead_sponsor_name":"Anumana, Inc.","has_results":false},{"nct_id":"NCT06697340","title":"Braden Pressure Ulcer Scale for Prediction of the Intensive Care Length of Stay","phase":"","overall_status":"COMPLETED","enrollment_count":11000,"lead_sponsor_name":"Ankara City Hospital Bilkent","has_results":false},{"nct_id":"NCT04985981","title":"The Prediction of Anastomotic Insufficiency Risk After Colorectal Surgery (PANIC) Study","phase":"","overall_status":"SUSPENDED","enrollment_count":11000,"lead_sponsor_name":"Michel Adamina, MD","has_results":false},{"nct_id":"NCT07207031","title":"Acute Kidney Injury - Epidemiology in Intensive Care Unit Patients 2: an International Multicenter Cohort Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10642,"lead_sponsor_name":"University Hospital, Ghent","has_results":false},{"nct_id":"NCT07096973","title":"Cardiac REhabilitation COhort at the Medicine Campus DaVos to invEstigate Recovery","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Hochgebirgsklinik Davos","has_results":false},{"nct_id":"NCT05257863","title":"Development of Machine Learning Models for the Prediction of Complications After Colonic, Colorectal and Small Intestine Anastomosis in Psychiatric and Non-psychiatric Patient Collectives (P-Study)","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Dr. Med Anas Taha","has_results":false},{"nct_id":"NCT07484243","title":"Clinical Cohort Construction and Therapeutic Effect Evaluation of Integrated Traditional Chinese and Western Medicine in the Treatment of Rheumatoid Arthritis","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Yuanyuan Zhang","has_results":false},{"nct_id":"NCT05884645","title":"The DAnish VIdeo IntubaTION (DA-VITION) Study","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Lise Aunsholt","has_results":false},{"nct_id":"NCT07429929","title":"Saudi Emergency Laparotomy Audit","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"King Faisal Specialist Hospital & Research Center","has_results":false},{"nct_id":"NCT04189822","title":"Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT07267117","title":"Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT02208154","title":"Ecological Effects of Decolonisation Strategies in Intensive Care","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":8665,"lead_sponsor_name":"MJM Bonten","has_results":false},{"nct_id":"NCT03523962","title":"Pre-operative Alcohol Skin Solutions in Fractured Extremities","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":8485,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":true},{"nct_id":"NCT06324682","title":"ConTempoRary Cardiac Stimulation in Clinical practicE: lEft, BivEntriculAr, Right, and conDuction System Pacing","phase":"","overall_status":"RECRUITING","enrollment_count":8400,"lead_sponsor_name":"University Hospital of Ferrara","has_results":false},{"nct_id":"NCT06888206","title":"Impact of Age on Mortality in Critically Ill Adult Patients in Nepal- a Single Center Retrospective Study of 5 Years.","phase":"","overall_status":"COMPLETED","enrollment_count":8189,"lead_sponsor_name":"Tribhuvan University Teaching Hospital, Institute Of Medicine.","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT06200857","title":"Impact of Socioeconomic and Territorial Inequalities on Surgical Management of Sigmoid Diverticulitis","phase":"","overall_status":"COMPLETED","enrollment_count":6800,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT05363358","title":"A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","phase":"","overall_status":"COMPLETED","enrollment_count":6086,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT04744415","title":"Hospitalizations During Pandemia in the Italian Coronary Care Unit Network","phase":"","overall_status":"COMPLETED","enrollment_count":6054,"lead_sponsor_name":"Heart Care Foundation","has_results":false},{"nct_id":"NCT03869619","title":"REal World Data in LYmphoma and Survival in Adults","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03959085","title":"Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":5951,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02883049","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5949,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07495436","title":"Video Versus Direct Laryngoscopy for Tracheal Intubation in Pediatric Surgery","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":5562,"lead_sponsor_name":"Hospital Clinico Universitario de Santiago","has_results":false},{"nct_id":"NCT06605144","title":"Canadian Critical Care Comparative Effectiveness Platform","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":5500,"lead_sponsor_name":"Université de Sherbrooke","has_results":false},{"nct_id":"NCT06339255","title":"Italian Observational Study on CAR-T Therapy for Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":5300,"lead_sponsor_name":"Paolo Corradini","has_results":false},{"nct_id":"NCT07375602","title":"A Multimodal AI Prediction Model for Complications After Transcatheter Closure of Perimembranous VSD in Children","phase":"","overall_status":"RECRUITING","enrollment_count":5249,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT07355023","title":"AI-Enabled Electrocardiogram-Guided Guideline-Directed Medical Therapy on Incident Left Ventricular Dysfunction: A Target Trial Emulation Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Tri-Service General Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}